CuraCell holds final advice meeting with German regulator PEI

CuraCell today held its second advice meeting with the German regulator PEI (Paul-Ehrlich Institut). The first meeting was held on the 27th of October, focused on non-clinical questions related to the company’s first product, CC-38. Today’s meeting was dedicated to the study protocol.

The feedback received supports CuraCell to move ahead and prepare the first-in-human clinical trial application (phase 1/2a). The trial is planned to include advanced prostate and colorectal cancer patients.